Evidence comparison

Retatrutide vs Tirzepatide

Tirzepatide is an approved GIP and GLP-1 agonist. Retatrutide adds glucagon-receptor activity and remains investigational. Cross-trial percentages are not head-to-head evidence.

Compare mechanisms

Receptor targets differ, which changes the scientific hypothesis.

Compare approval status

Approved labeling and investigational trial data are different evidence levels.

Avoid cross-trial ranking

Populations, durations, estimands, and protocols differ across studies.

Side-by-side evidence map

Question	Retatrutide	Tirzepatide
Mechanism	GLP-1, GIP, and glucagon agonism	GIP and GLP-1 agonism
Regulatory status	Investigational	FDA-approved for specific indications
Core evidence	Phase 2 peer-reviewed; Phase 3 program active	Large phase 3 programs and approved labeling
Direct comparison	No head-to-head trial	No head-to-head trial

How to read the numbers

A larger percentage reported in one trial does not prove superiority over a result from another trial. A valid treatment comparison requires a head-to-head design or a carefully specified indirect analysis.